Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

(2021) Yanna Lei et al.   Frontiers in Oncology

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Advances in immunotherapy for hepatocellular carcinoma

(2021) Bruno Sangro et al.   Nature Reviews Gastroenterology & Hepatology

Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma

(2021) Petros Fessas et al.   Cancers

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

(2020) Michael S Lee et al.   LANCET ONCOLOGY

Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma

(2020) Ankur Sharma et al.   CELL

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Bystander CD4+ T cells: crossroads between innate and adaptive immunity

(2020) Hong-Gyun Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma

(2020) Ching Ngar Wong et al.   LIVER INTERNATIONAL

multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data

(2020) Sebastian Canzler et al.   BMC BIOINFORMATICS

Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC

(2019) Roser Pinyol et al.   CLINICAL CANCER RESEARCH

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

(2019) David J. Pinato et al.   BRITISH JOURNAL OF CANCER

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

(2019) Marina Ruiz de Galarreta et al.   Cancer Discovery

Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation

(2019) Pedro Berraondo et al.   Cancer Discovery

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer

(2019) Yu-Jung Kim et al.   LUNG CANCER

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

(2019) Jonathan A. Trujillo et al.   Journal for ImmunoTherapy of Cancer

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

(2018) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

(2018) David F. McDermott et al.   NATURE MEDICINE

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity

(2018) Shishir Shetty et al.   Nature Reviews Gastroenterology & Hepatology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies

(2018) James J Harding et al.   CLINICAL CANCER RESEARCH

Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies

(2017) Wenjun Zhang et al.   LABORATORY INVESTIGATION

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

(2015) Sachet A Shukla et al.   NATURE BIOTECHNOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid

(2013) R. M. Dunham et al.   JOURNAL OF IMMUNOLOGY

Increased tumor-infiltrating CD8+Foxp3+ T lymphocytes are associated with tumor progression in human gastric cancer

(2012) Liu-sheng Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib

(2012) A. Lachenmayer et al.   CLINICAL CANCER RESEARCH

The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature

(2012) R. J. deLeeuw et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas

(2012) Harry H. Yoon et al.   PLoS One

DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo

(2011) J.-L. Li et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

NetMHCcons: a consensus method for the major histocompatibility complex class I predictions

(2011) Edita Karosiene et al.   IMMUNOGENETICS